We are live on !
Find out more
Foundry Partners Portfolio holdings
AUM
$1.89B
Turnover
15.38%
1-Year Est. Return
9.84%
Foundry Partners's holdings are now reported by CSM Advisors.
This Fund
S&P 500
This Quarter Est. Return
+0.53%
1 Year Est. Return
+9.84%
3 Year Est. Return
+44.42%
5 Year Est. Return
+233.04%
10 Year Est. Return
+297.72%
AUM
$1.99B
AUM Growth
-$31M
(-1.5%)
Cap. Flow
+$2.55M
Cap. Flow % of AUM
Cap. Flow %
0.13%
Top 10 Holdings %
Top 10 Hldgs %
17.9%
Holding
309
New
24
Increased
123
Reduced
118
Closed
40
Avg Time Held
2.7
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$22.7M |
| 2 |
Pfizer
PFE
|
+$21.5M |
| 3 |
Quest Diagnostics
DGX
|
+$16.8M |
| 4 |
Mosaic
MOS
|
+$15.1M |
| 5 |
Hancock Whitney
HWC
|
+$13.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$16M |
| 2 |
Merck
MRK
|
+$15.9M |
| 3 |
LyondellBasell Industries
LYB
|
+$15.7M |
| 4 |
Phillips 66
PSX
|
+$13.8M |
| 5 |
Johnson & Johnson
JNJ
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.91% |
| 2 | Industrials | 16.45% |
| 3 | Technology | 11.11% |
| 4 | Healthcare | 10.84% |
| 5 | Consumer Discretionary | 6.97% |
Similar funds
PAME
Foundry Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Foundry Partners held 309 positions worth $1.99B, down 1.5% from $2.02B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Foundry Partners's Q4 2024 filing shows 24 new, 123 increased, 118 reduced and 40 closed positions. Its largest new stake was Bristol-Myers Squibb: 406,683 shares worth $23M. The largest sale was GSK, an estimated $16M.
By sector, the portfolio is most concentrated in Financials at 25% of assets, up from 21% a quarter earlier, followed by Industrials and Technology.
- Foundry Partners's largest Q4 2024 buy was Bristol-Myers Squibb: 406,683 shares worth $23M.
- Foundry Partners added most to Walt Disney in Q4 2024, an estimated $8.81M increase.
- Foundry Partners's biggest Q4 2024 reduction was Johnson & Johnson, cutting an estimated $11.1M.
- Foundry Partners fully exited GSK in Q4 2024, selling an estimated $16M.
- Foundry Partners's ten largest holdings make up 18% of its $1.99B portfolio in Q4 2024.
- Foundry Partners opened 24 new positions and closed 40 in Q4 2024.
- Foundry Partners's portfolio value fell 1.5% quarter-over-quarter to $1.99B.
Based on Foundry Partners's 13F filing for Q4 2024, filed 12 Feb 2025.